The U.K. agreed to relax certain drug‑pricing rules and increase spending on medicines in exchange for a U.S. decision not to impose tariffs on British‑origin pharmaceuticals, ingredients and devices for three years. The deal raises NICE’s cost‑effectiveness threshold and reduces mandated manufacturer rebates to the NHS, changes that ministers say will speed access and attract life‑science investment. Officials framed the arrangement as a tradeoff to preserve market access to the U.S. while bolstering U.K. investment; industry groups hailed the move as a way to reverse a recent pullback in R&D spending. The pact may alter global pricing dynamics and affect launch sequencing and manufacturer strategy across markets.